Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01005277|
Recruitment Status : Active, not recruiting
First Posted : October 30, 2009
Last Update Posted : October 9, 2017
RATIONALE: Studying samples of DNA from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is looking at biomarkers in DNA samples from patients with acute lymphoblastic leukemia or acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene expression analysis Genetic: microarray analysis Genetic: polymorphism analysis|
- Collect DNA samples from patients with cytogenetically, well characterized, and uniformly treated acute lymphoblastic leukemia or acute myeloid leukemia for use in analysis of a wide range of host factors influencing etiology and outcome of the disease.
- Identify host factors that can be determined at onset of treatment to predict outcome of chemotherapy, and thus modify the therapy administered.
OUTLINE: Previously collected DNA samples are analyzed for polymorphisms at a variety of loci. Gene expression and expression profiles are correlated with genotype and therapy outcomes.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Genetic Polymorphisms in ALL Samples Submitted to Gene Array Analysis|
|Study Start Date :||April 2002|
|Estimated Primary Completion Date :||January 2100|
- Collection of DNA samples for use in analysis of a wide range of host factors influencing etiology and outcome of disease
- Host factors that can be determined at onset of treatment to predict outcome of chemotherapy, and thus modify the therapy administered
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01005277
|Study Chair:||Stella M. Davies, MBBS, PhD||Children's Hospital Medical Center, Cincinnati|